The rising incidence of acquired haemophilia A in Germany

Abstract

Acquired haemophilia A (AHA) is a rare autoimmune disorder resulting from the formation of neutralizing antibodies against coagulation factor VIII (FVIII). 1,2 It is characterized by a sudden onset of bleeding in patients, who typically do not have a previous history of haemostasis disorder. Most patients present with severe

The statistical risk of diagnosing coincidental acquired hemophilia A following anti‐SARS‐CoV‐2 vaccination

“…The incidence of AHA in Europe is believed to be 1.5 to 6 per 1.000.000, and 85% of the patients are older than 65 years. [4][5][6] Based on these data, we would expect 11 to 44 AHA cases per year in the age group >65 years in Switzerland.…”

Should emicizumab be used in patients with acquired hemophilia A?

“…7 The disorder is rare, with an estimated incidence of 1 to 6 cases per million per year. 8,9 Patients typically present with a sudden onset of bleeding and a prolonged activated partial thromboplastin time (APTT). Large subcutaneous hematomas, occurring spontaneously or after minor trauma, are characteristic of the disease ( Figure 1A).…”

“…Inhibitors in AHA are neutralizing autoantibodies against FVIII that develop spontaneously or in association with other autoimmune disorders, malignancy, pregnancy, infection, or certain medications 7 . The disorder is rare, with an estimated incidence of 1 to 6 cases per million per year 8,9 . Patients typically present with a sudden onset of bleeding and a prolonged activated partial thromboplastin time (APTT).…”

Recombinant porcine factor VIII: Lessons from the past and place in the management of hemophilia A with inhibitors in 2021

“…A stroke was reported in an individual who received repeated rFVIIa doses because of surgical procedures while on emicizumab. 7 We hypothesize that in frail individuals with acquired hemophilia A and cardiovascular risk factors, r‐pFVIII might be a good alternative to bypassing agents when concomitant treatment with emicizumab is needed. Moreover, as r‐pFVIII can be monitored using one‐stage clotting factors or chromogenic assays, treatment decision making can be easily guided to make the concomitant treatment with emicizumab effective and safe.…”

“… 5 Its incidence is estimated to be one case per million individuals/year, 6 but due to the lack of adequate diagnosis, the real incidence might be higher, up to six cases per million individuals/year. 7 …”